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Abstract
The rate of eradication of Helicobacter pylori with standard triple therapy using omeprazole, amoxicillin and clarithromycin (OAC) is
unacceptable in populations with high rates of clarithromycin resistance (15–20%). The aim of this study was to compare the efﬁcacy of
10-day OAC therapy as the ﬁrst-line treatment in patients diagnosed by culture with antimicrobial susceptibility or diagnosed by a 13C-
labelled urea breath test (UBT) without antimicrobial susceptibility in an area where the clarithromycin resistance rate was 15–20%.
This was a retrospective cohort study of 266 patients, recruited consecutively throughout 2008. A total of 247 H. pylori-infected
patients received antibiotic therapy (221 received the 10-day OAC therapy and 26 received other regimens) of which 134 patients were
diagnosed by culture of gastric samples followed by antimicrobial susceptibility testing and 113 were diagnosed by UBT. In all patients,
the eradication of H. pylori was checked by UBT. The cost of eradication by 10-day OAC treatment was assessed in each patient. The
success rate of 10-day OAC therapy in patients diagnosed by culture and by UBT was 88% (103/117) and 49% (51/104), respectively
(p <0.0005). The treatment was also more cost-effective in the former of these two groups (€571 versus €666). To perform culture
and antimicrobial susceptibility of the H. pylori isolates was a more successful and cost effective strategy than empirical 10-day OAC
treatment in populations with high rates of resistance to clarithromycin.
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Introduction
The prevalence of Helicobacter pylori infection ranges from
30% to 50% in developed countries and from 70% to 80% in
developing countries [1]. Some individuals in the infected
populations will develop chronic atrophic gastritis, peptic
ulcer disease, gastric mucosa-associated lymphoid tissue lym-
phoma, and even gastric adenocarcinoma. The treatment of
gastrointestinal diseases related to H. pylori infection is rou-
tinely required in clinical practice.
Standard triple therapy, a combination of a proton pump
inhibitor with two antibiotics (clarithromycin + amoxicillin or
metronidazole) for 7 days is only recommended for the
treatment of H. pylori infections in geographical areas where
the rates of resistance to clarithromycin are below 15–20%
or where resistance to metronidazole is below 40% [2]. In
the regions where the rate of resistance to clarithromycin is
>20% alternative eradication regimens have been proposed,
such as the sequential triple therapy, bismuth quadruple ther-
apy, and concomitant quadruple therapy, based on omepra-
zole plus three of the following antibiotics: clarithromycin,
amoxicillin, metronidazole, tetracycline or bismuth, or alter-
natively testing antimicrobial susceptibility of the H. pylori iso-
late before treatment [3].
The appropriate use of antibiotics requires the prescription
of regimens that are sufﬁcient to optimize the eradication of
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H. pylori, maximizing their efﬁcacy, while avoiding prolonga-
tion of treatment beyond the period necessary to eradicate
the bacteria. For this reason, it is recommended that refer-
ence laboratories monitor the primary resistance, performing
culture and antimicrobial susceptibility testing, to establish
which therapies will achieve the higher eradication rates in
each area. In our region, the Basque Country (Spain), resis-
tance to clarithromycin was >15% in the last 5 years. The
objective of the present study was to assess the usefulness of
antimicrobial susceptibility in the eradication of H. pylori.
Patients and Methods
This was a retrospective cohort study of 266 patients,
recruited consecutively throughout 2008 when they attended
the Donostia Hospital, in San Sebastian (Basque Country) or
any of three specialist care centres under the management
of the Donostia Hospital. All these patients were diagnosed
with H. pylori infection through culture of gastric biopsy or
string test followed by antimicrobial susceptibility testing
(148 cases) or by 13C-labelled urea breath test (UBT; 118
cases; Fig. 1). Patients had dyspeptic symptoms, peptic ulcer
disease or ﬁrst-degree family history of gastric cancer or gas-
tric mucosa-associated lymphoid tissue lymphoma (Table 1).
The exclusion criteria were being younger than 18 years old,
having any severe concomitant disease, having previously
undergone H. pylori eradication treatment or gastric surgery,
or intolerance to any antimicrobial drugs.
Oral gastroscopies to obtain biopsies of the gastric body
and antrum were performed depending on the digestive signs
and symptoms following the recommendations of the special-
ist. The string test consisted of a capsule attached to a highly
absorbent nylon string, which is swallowed to obtain gastric
secretions using a procedure previously validated by our
group [4,5]. Antimicrobial susceptibility against metronida-
zole, clarithromycin, levoﬂoxacin, tetracycline and amoxicillin
was measured using the E-test (bioMe´rieux SA, Marcy l’Eto-
ile, France). Overall, during 2008, 437 H. pylori isolates were
tested for antimicrobial susceptibility at the Microbiology
Department of the Donostia Hospital (Table 2). For the
UBT, a 100-mg UBTest (Otsuka Pharmaceutical Europe, Bar-
celona, Spain) was used. Breath samples were analysed using
a mass spectrophotometer (NDIRS, Otsuka Pharmaceutical)
and were considered positive when the value of 13C (differ-
ence between baseline and post values) was over 2.5 delta
units (>2.5%).
Patients diagnosed by culture (biopsy or string test) were
treated with a regimen based on the antimicrobial suscepti-
bility. In 117 patients infected with an isolate sensitive to
clarithromycin, the therapy used was 10-day OAC (a twice
daily combination of omeprazole, 20 mg; amoxicillin, 1 g and
clarithromycin, 500 mg for 10 days). When resistance to
clarithromycin was detected (17 cases), the classical quadru-
ple treatment with bismuth (OBMT; omeprazole/bismuth/
metronidazole/tetracycline) for 10–14 days and four different
10-day triple therapies were used, based on antimicrobial
susceptibility. In these four triple regimens the clarithromycin
266 consecutive H. Pylori – positive naive patients
Culture on gastric
biopsies/string test with antibiogram
n = 148
UBT
n = 118
Eradication not confirmed with
UBT n = 14 (9.46%)
Eradication not confirmed with
UBT n = 5 (4.24%)
Treatment regimens
n = 134
Treatment regimens
n = 113
OAC  n = 117
Others n = 17
OAC  n = 104
Others n = 9
UBT: 13C-urea breath test (100 mg UBT Otsuka), O, omeprazole; A, amoxicillin; C, clarithromycin
FIG. 1. Flow diagram of subject progress
through the of study phases.
TABLE 1. Demographic and clinical characteristics of
patients enrolled in the study
Variable
Diagnostic method
p
Culture with
antibiogram
UBT without
antibiogram
No. of patients 134 113
Sex, male/female 71/63 50/63 0.2
Age (years) mean ± SD 48.3 ± 14.4 48.1 ± 14.2 0.93
Indication, n (%)
Dyspepsia 72 (53.7) 58 (51.3) 0.8
Peptic ulcer disease 49 (36.5) 38 (33.6) 0.7
Gastric cancer in
ﬁrst-degree relatives
11 (8.2) 17 (15.1) 0.1
Gastric MALT lymphoma 2 (1.6) – 0.5
UBT, 13C urea breath test; MALT, mucosa-associated lymphoid tissue.
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of the standard triple therapy was swapped for levoﬂoxacin
(500 mg), metronidazole (500 mg), rifabutin (150 mg) or
doxycycline (100 mg), all given twice daily (OAL, OAM,
OAR and OAD, respectively).
Patients diagnosed by UBT (113 cases) were treated empir-
ically, with the ﬁrst-line eradication triple therapy 10-day
OAC (in 104 cases) but in nine cases other regimens: OAM,
OAL, OML (twice daily omeprazole, 20 mg; metronidazole,
500 mg and levoﬂoxacin, 500 mg for 10 days) or OMC
(twice daily omeprazole, 20 mg and clarithromycin, 500 mg
plus thrice daily metronidazole, 500 mg for 10 days) were
used at the discretion of the gastroenterologist (Table 3).
To conﬁrm the eradication of H. pylori the UBT was per-
formed 6–8 weeks after the end of the treatment in all
patients. The deﬁnitive results, as well as adherence to ther-
apy and any adverse effects of the treatment, were assessed
during patient follow-up visits.
Statistical analysis
To compare the differences between the two groups, the
Fisher test was used for qualitative variables and the Stu-
dent’s t-test for quantitative variables. Differences were con-
sidered to be signiﬁcant when the p values were below 0.05.
Cost analysis
To estimate the cost of the eradication of H. pylori, the
direct costs of visits to the doctor, diagnostic methods and
antimicrobial drugs were assessed. Costs of the ﬁrst consul-
tation (€110), follow-up visit (€50), gastroscopy with biopsy
(€202.20), antimicrobial susceptibility test (€40), string test
(€22), the breath test (€46.50) and the antimicrobial drugs
(€25) were taken from the 2008 price list of the institution
(Donostia Hospital).
Results
Of the 266 patients initially included, 19 were excluded
because conﬁrmation of eradication was not performed (14
in the group of patients with an antibiogram and ﬁve in the
UBT group), and 247 (121 men and 126 women) were ﬁnally
included (Fig. 1). These exclusions do not interfere with the
results. The rate of success of the 10-day OAC therapy in
patients diagnosed by culture with clarithromycin susceptibil-
ity was 88% (103/117) while that in those treated with 10-
day OAC and diagnosed by UBT was 49% (51/104)
(p <0.0005). When all initial treatment regimens were con-
sidered, the rates of eradication were 84.3% (113/134) and
50.4% (57/113) for patients diagnosed by culture with anti-
microbial susceptibility or by UBT, respectively (p <0.0005;
Table 3).
Among the 14 patients in the group diagnosed by culture
with antimicrobial susceptibility, in whom eradication was
not achieved by OAC, four cases of resistance to metronida-
zole and two to levoﬂoxacin were detected. Among the 17
patients with resistance to clarithromycin, who received
other types of eradication regimens according to the antimi-
crobial susceptibility, isolates obtained in 11 patients also
showed resistance to metronidazole (seven patients), levo-
ﬂoxacin (two patients) or both (two patients).
In 30 of the 53 patients diagnosed by UBT in whom eradi-
cation was not achieved with 10-day OAC, a second treat-
ment was given based on various different regimens (19 with
TABLE 2. Percentage of Helicobacter pylori-resistant isolates
in Gipuzkoa (Basque country) 2006–10
Year 2006 2007 2008 2009 2010
No. of isolates 350 383 437 677 770
Metronidazole 32.0 38.8 37.2 37.2 41.4
Clarithromycin 15.7 17.8 21.1 17.6 18.1
Levoﬂoxacin 11.7 19.3 15.1 16.1 16.6
Tetracycline 0 0 0 0.6 0.4
Amoxicillin 0 0 0 0 0
TABLE 3. Efﬁcacy of Helicobacter
pylori eradication with different
treatment therapies
Diagnostic method
Culture with antibiogram (n = 134 patients) UBT without antibiogram (n = 113)
Treatment
therapies
No.
patients
No.
eradication
Treatment
therapies
No.
patients
No.
eradication
OAC 117 103a OAC 104 51a
OAL 6 3 OAM 5 5
OAM 4 3 OAL 1 0
OBTM 3 3 OML 1 0
OAD 3 1 OMC 2 1
OAR 1 0
134 113b 113 57b
ap (103 vs. 51) <0.0005.
bp (113 vs. 57) <0.0005.
O, omeprazole; A, amoxicillin; C, clarithromycin; L, levoﬂoxacin; M, metronidazole; B, tripotassium dicitrato bismut-
hate; T, tetracycline; D, doxycycline; R, rifampicin.
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OAL, ﬁve with OAM, ﬁve with OBMT and one re-treated
with OAC). With these second treatments, eradication was
achieved in 24 of the 30 (80%) cases; with treatment success
in 14 of the 19 (73.6%) patients treated with OAL.
Some adverse effects were observed in 31 (14%) of the
221 total patients treated with 10-day OAC (11 cases of
altered taste, eight of diarrhoea, six of stomach ache, four of
headache and two of oral candidiasis), nonetheless all
patients completed the full treatment.
The average cost of the eradication with 10-day OAC was
€571.20 per patient when diagnosis was made by culture
with antimicrobial susceptibility, and €666.80 in the UBT
group, where patients were empirically treated.
Overall, in 2008, H. pylori resistance rates were 37.2% for
metronidazole (MIC >4 mg/L), 21.1% for clarithromycin
(MIC >1 mg/L according to the recommendation of the CLSI
[6]) and 15.1% for levoﬂoxacin (MIC >2 mg/L). No resistance
was detected to tetracycline (MIC >4 mg/L) or amoxicillin
(MIC <1 mg/L). A total of 51.2% of all isolates were resistant
to at least one type of antibiotic, and 14.9% of the isolates
were multi-resistant. Notably, the rate of the double resis-
tance to clarithromycin and metronidazole was 8.9%.
Discussion
The commonest cause of failure to eradicate H. pylori is anti-
biotic resistance and this has increased, particularly resis-
tance to clarithromycin. In the Basque Country (Spain), from
1994 to 1998, considering 1419 H. pylori isolates, the primary
resistance to clarithromycin was 10.7% (rising year on year:
5.6% in 1994, 7% in 1995, 8.5% in 1996, 12.9% in 1997 and
19.5% in 1998) [7]. In the 5-year period 2006–10, in a total
of 2617 H. pylori isolates the primary resistance to clarithro-
mycin reached 18% (15.7% in 2006, 17.8% in 2007, 21.1% in
2008, 17.6% in 2009 and 18.1% in 2010; Table 2). In Europe,
primary resistance to this antibiotic in adults has a north/
south gradient, with prevalence being lower in northern
European countries (2–11%) and higher in the south (12–
22%) [8,9].
Across Europe [9], around 10% of the H. pylori isolates
are resistant to more than one family of antibiotics. In our
region, multi-resistance was detected in 10.5% of the H. pylori
isolates in the period 1994–98 and in 14.9% in 2008. Double
resistance to clarithromycin and metronidazole was 8.9% in
the present study, higher than the ﬁgure cited in a recent lit-
erature review [9], where the highest rate was that for Japan
(6.6%). This situation makes it even more difﬁcult for
H. pylori eradication treatments to be successful and
increases the need to search for other therapeutic strategies.
In two European multicentre trials [10,11] (MACH1 and
MACH2), reported in 1996 and 1999, the efﬁcacy of the 7-
day OAC and OMC triple therapies for the eradication of
H. pylori was conﬁrmed. Notably, in the MACH2 study the
rate of resistance to clarithromycin was just 3%. At the Euro-
pean Helicobacter Study Group (EHSG) meeting [12], held in
Maastricht (1997), the standard triple therapy (7–10 days of
OAC) was recommended as the ﬁrst-line treatment for
H. pylori infection (ﬁrst consensus conference). Since then,
the eradication success according to intention-to-treat (ITT)
analysis has fallen from 90% to 75–80% in regions with high
rates of resistance to clarithromycin [8,13]. In 2010, Graham
and Fischbach [14], reviewed 121 studies on the efﬁcacy of
the ﬁrst-line of treatment in adults carried out between 1997
and 2009, and demonstrated that only 18% of adults have
more than an 85% chance of the infection being successfully
eradicated (on the basis of ITT analysis). Moreover, in 60%
of these studies the success of eradication of H. pylori did not
reach 80% (again, with ITT analysis). Some of these studies
were carried out in populations of Central and Southern Eur-
ope with resistance rates to clarithromycin >18%.
To increase the eradication rates with standard triple ther-
apy (OAC) it has been suggested that the dose of proton
pump inhibitors or the duration of treatment be increased.
Villoria et al. [15]. reported that the rate of eradication with
OAC treatments increases by 8% if the dose of omeprazole is
doubled with respect to that normally used and Fuccio et al.
[16] reported an increase in the eradication of 4–5% when the
duration of the treatment is 10–14 days, instead of 7 days.
The recommended duration of the triple OAC is 10–14 days
in the USA [17] whereas it is 7 days in Europe [2]. Nonethe-
less, it is accepted that with a prevalence of resistance to clari-
thromycin higher than 15–20%, a standard triple therapy,
including macrolides, should not be used on an empirical basis.
The inappropriate use of antibiotics in the community,
together with population migration, has changed the levels of
resistance within countries, and also within small geographi-
cal areas. This makes it necessary to search for treatment
regimens that achieve 90% eradication, according to ITT
analysis, in speciﬁc local communities knowing the local levels
of antibiotic resistances, rather than following recommenda-
tions in general guidelines and consensus. To date, the effec-
tiveness of various empirical eradication therapies has been
conﬁrmed, including the sequential triple therapy (omepra-
zole 20 mg + amoxicillin 1 g twice daily given for the ﬁrst
5 days followed by a triple therapy including omeprazole
20 mg, clarithroycin 500 mg and metronidazole 500 mg, all
twice daily, for the remaining 5 days), the classical bismuth-
containing quadruple therapy (omeprazole 20 mg twice
daily + bismuth salt 120 mg, tetracycline 500 mg and metro-
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nidazole 250 mg, four times a day, for 10–14 days) and con-
comitant quadruple therapy (triple therapy OAC + metroni-
dazole 500 mg, all twice daily for 10 days) as Graham and
Fischbach have stated [14].
In 2004, Me´graud [18] reviewed several clinical trials pub-
lished between 1999 and 2003 to assess the efﬁcacy of the
standard triple therapy (OAC) based on the H. pylori antibi-
otic sensitivity. The study that included 1975 isolates showed
that the rate of eradication using the OAC triple treatment
decreased from 87.8% to 18.3%, when H. pylori were suscep-
tible or resistant to clarithromycin. In the same study, with
656 isolates analysed, the eradication efﬁciency of the OAM
triple regimen decreased by 25% (from 89.4% to 64.4%)
when H. pylori isolates were susceptible or resistant to met-
ronidazole.
The poor efﬁcacy of the empirical OAC triple therapy in
the eradication of H. pylori when the prevalence of clarithro-
mycin resistance is higher than 20% represents a challenge for
clinicians and it was the reason for the present study. Our
ﬁndings indicate that this problem, compounded by the exis-
tence of multi-resistance to various families of antibiotics and
the increase in resistance to other antimicrobial drugs [9,19],
may be addressed by the appropriate use of antibiotics, in a
less costly way and with courses kept as short as possible.
Furthermore, high rates of clarithromycin resistance (around
50%) are always present in cases when clarithromycin-based
ﬁrst-line treatment has failed. This means that in such a setting
susceptibility testing would always be mandatory.
To perform antimicrobial susceptibility before deciding on
a deﬁnitive treatment is essential in populations with high
rates of resistance to clarithromycin such as ours, because
the eradication rates are improved and treatments are more
cost-effective.
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